echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > The State Food and Drug Administration conditionally approved the marketing of Linplisset tablets

    The State Food and Drug Administration conditionally approved the marketing of Linplisset tablets

    • Last Update: 2023-01-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Recently, the State Medical Products Administration conditionally approved the listing of Class 1 innovative drug Linplisset tablets (trade name: Intarui) declared by Shanghai Yingli Pharmaceutical Co.
    , Ltd.
    through the priority review and approval process
    The drug is an innovative drug independently developed in China with independent intellectual property rights, and is suitable for adult patients
    with relapsed or refractory follicular lymphoma who have received at least two systemic treatments in the past.
    Linplisset is a selective inhibitor
    of the δ isoform (PI3Kδ) of phosphatidylinositol-3-kinase.
    Linplisset tablets can inhibit the expression of PI3Kδ protein and reduce the phosphorylation level of AKT protein, thereby inducing apoptosis and inhibiting the proliferation
    of malignant B cells and primary tumor cells.
    The listing of this drug provides a treatment option
    for adult patients with relapsed and refractory follicular lymphoma after treatment with existing treatments.
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.